MREO
Price
$1.78
Change
+$0.07 (+4.09%)
Updated
Jul 17 closing price
Capitalization
283.02M
81 days until earnings call
RARE
Price
$27.41
Change
+$0.10 (+0.37%)
Updated
Jul 17 closing price
Capitalization
2.59B
13 days until earnings call
Interact to see
Advertisement

MREO vs RARE

Header iconMREO vs RARE Comparison
Open Charts MREO vs RAREBanner chart's image
Mereo BioPharma Group
Price$1.78
Change+$0.07 (+4.09%)
Volume$3.41M
Capitalization283.02M
Ultragenyx Pharmaceutical
Price$27.41
Change+$0.10 (+0.37%)
Volume$2.15M
Capitalization2.59B
MREO vs RARE Comparison Chart in %
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. RARE commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (MREO: $1.78 vs. RARE: $27.41)
Brand notoriety: MREO and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 142% vs. RARE: 129%
Market capitalization -- MREO: $283.02M vs. RARE: $2.59B
MREO [@Biotechnology] is valued at $283.02M. RARE’s [@Biotechnology] market capitalization is $2.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, MREO is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • MREO’s TA Score: 5 bullish, 5 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MREO is a better buy in the short-term than RARE.

Price Growth

MREO (@Biotechnology) experienced а +5.33% price change this week, while RARE (@Biotechnology) price change was -11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +40.41%.

Reported Earning Dates

MREO is expected to report earnings on Nov 18, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.59B) has a higher market cap than MREO($283M). RARE YTD gains are higher at: -34.847 vs. MREO (-49.143). MREO has higher annual earnings (EBITDA): -44.87M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. MREO (62.5M). MREO has less debt than RARE: MREO (747K) vs RARE (38.3M). RARE has higher revenues than MREO: RARE (591M) vs MREO (0).
MREORAREMREO / RARE
Capitalization283M2.59B11%
EBITDA-44.87M-449.9M10%
Gain YTD-49.143-34.847141%
P/E RatioN/AN/A-
Revenue0591M-
Total Cash62.5M494M13%
Total Debt747K38.3M2%
FUNDAMENTALS RATINGS
MREO vs RARE: Fundamental Ratings
MREO
RARE
OUTLOOK RATING
1..100
551
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9492
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (72) in the null industry is in the same range as RARE (75) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

MREO's Profit vs Risk Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

MREO's SMR Rating (98) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (92) in the Biotechnology industry is in the same range as MREO (94) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for RARE (100) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREORARE
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIDVX12.26N/A
N/A
Hartford Schroders Intl Multi-Cp Val A
RRMVX30.44N/A
N/A
T. Rowe Price Mid-Cap Value R
IEDZX13.67N/A
N/A
Voya Large Cap Value R6
KCVSX17.80N/A
N/A
Knights of Columbus Large Cap Value S
LEOOX9.10N/A
N/A
Lazard Enhanced Opportunities Open

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+4.09%
RARE - MREO
66%
Loosely correlated
+0.37%
TRDA - MREO
47%
Loosely correlated
N/A
CGON - MREO
43%
Loosely correlated
+9.13%
TERN - MREO
41%
Loosely correlated
+6.26%
NRIX - MREO
40%
Loosely correlated
-2.66%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+0.37%
MREO - RARE
66%
Closely correlated
+4.09%
IONS - RARE
49%
Loosely correlated
-1.40%
VCYT - RARE
46%
Loosely correlated
-3.77%
NRIX - RARE
46%
Loosely correlated
-2.66%
CRNX - RARE
45%
Loosely correlated
+3.51%
More